| Targeting antibiotic resistance MF Chellat, L Raguž, R Riedl Angewandte Chemie International Edition 55 (23), 6600-6626, 2016 | 544 | 2016 |
| New perspectives in oral peptide delivery AT Zizzari, D Pliatsika, FM Gall, T Fischer, R Riedl Drug discovery today 26 (4), 1097-1105, 2021 | 89 | 2021 |
| Design and structural evolution of matrix metalloproteinase inhibitors T Fischer, N Senn, R Riedl Chemistry–A European Journal 25 (34), 7960-7980, 2019 | 68 | 2019 |
| Probing the scope of the asymmetric dihydroxylation of polymer-bound olefins. Monitoring by HRMAS NMR allows for reaction control and on-bead measurement of enantiomeric excess R Riedl, R Tappe, A Berkessel Journal of the American Chemical Society 120 (35), 8994-9000, 1998 | 68 | 1998 |
| A structural view on medicinal chemistry strategies against drug resistance S Agnello, M Brand, MF Chellat, S Gazzola, R Riedl Angewandte Chemie International Edition 58 (11), 3300-3345, 2019 | 61 | 2019 |
| Inhibitory antibodies designed for matrix metalloproteinase modulation T Fischer, R Riedl Molecules 24 (12), 2265, 2019 | 45 | 2019 |
| Combinatorial de novo synthesis of catalysts: how much of a hit-structure is needed for activity? A Berkessel, R Riedl Journal of Combinatorial Chemistry 2 (3), 215-219, 2000 | 44 | 2000 |
| Merging Allosteric and Active Site Binding Motifs: De novo Generation of Target Selectivity and Potency via Natural‐Product‐Derived Fragments J Lanz, R Riedl ChemMedChem 10 (3), 451-454, 2015 | 43 | 2015 |
| Thermal Cleavage of the Fmoc Protection Group: FH–HES S Höck, R Marti, R Riedl, M Simeunovic Chimia 64 (3), 200-200, 2010 | 42 | 2010 |
| Approaching target selectivity by de novo drug design T Fischer, S Gazzola, R Riedl Expert opinion on drug discovery 14 (8), 791-803, 2019 | 40 | 2019 |
| Antibiotikaresistenzen gezielt überwinden MF Chellat, L Raguž, R Riedl Angewandte Chemie 128 (23), 6710-6738, 2016 | 40 | 2016 |
| Genomic effects of polyamide/DNA interactions on mRNA expression L Supekova, JP Pezacki, AI Su, CJ Loweth, R Riedl, B Geierstanger, ... Chemistry & biology 9 (7), 821-827, 2002 | 37 | 2002 |
| Pseudouridimycin: The First Nucleoside Analogue That Selectively Inhibits Bacterial RNA Polymerase. MF Chellat, R Riedl Angewandte Chemie (International ed. in English) 56 (43), 13184-13186, 2017 | 36 | 2017 |
| Targeted polypharmacology: discovery of a highly potent non-hydroxamate dual matrix metalloproteinase (MMP)-10/-13 inhibitor N Senn, M Ott, J Lanz, R Riedl Journal of medicinal chemistry 60 (23), 9585-9598, 2017 | 25 | 2017 |
| Highly oxygenated sesquiterpenes in Artemisia alba Turra M Todorova, A Trendafilova, K Danova, L Simmons, E Wolfram, B Meier, ... Phytochemistry 110, 140-149, 2015 | 24 | 2015 |
| Challenges with matrix metalloproteinase inhibition and future drug discovery avenues T Fischer, R Riedl Expert opinion on drug discovery 16 (1), 75-88, 2021 | 23 | 2021 |
| Drug design inspired by nature: crystallographic detection of an auto‐tailored protease inhibitor template FM Gall, D Hohl, D Frasson, T Wermelinger, PRE Mittl, M Sievers, R Riedl Angewandte Chemie International Edition 58 (12), 4051-4055, 2019 | 22 | 2019 |
| Emodin, a compound with putative antidiabetic potential, deteriorates glucose tolerance in rodents SA Eid, M Adams, T Scherer, H Torres-Gómez, MT Hackl, M Kaplanian, ... European journal of pharmacology 798, 77-84, 2017 | 22 | 2017 |
| Strategic Targeting of Multiple Water‐Mediated Interactions: A Concise and Rational Structure‐Based Design Approach to Potent and Selective MMP‐13 Inhibitors T Fischer, R Riedl ChemMedChem 8 (9), 1457, 2013 | 21 | 2013 |
| Fluorescence reporters for phosphodiesterase activity A Berkessel, R Riedl Angewandte Chemie: International Edition 36, 1481-1483, 1997 | 21 | 1997 |